respiratory

News

Update: MSD confirms $10bn takeover deal for Verona Pharma

MSD has agreed a $10bn takeover offer for respiratory drug specialist Verona Pharma and its fast-growing COPD therapy Ohtuvayre.

News

GSK claims first approval for Nucala in COPD

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

Stopwatch starts on reviews of GSK's long-acting asthma drug

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

Scrabble letters spelling out 'Deep Breath'

Verona says COPD drug is off to a flying start

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.

Digital

Digital biomarkers: Redefining respiratory care

Respiratory diseases, common examples of which include asthma and chronic obstructive pulmonary disease (COPD), affect one in five people in the UK.1 The economic burden of these

News

Study finds AZ's benralizumab a 'game-changer' in asthma

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks

Update: MSD confirms $10bn takeover deal for Verona Pharma

GSK claims first approval for Nucala in COPD

Stopwatch starts on reviews of GSK's long-acting asthma drug

Verona says COPD drug is off to a flying start

Digital biomarkers: Redefining respiratory care

Study finds AZ's benralizumab a 'game-changer' in asthma

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

respiratory

Editor's Picks